The P2X(7) purinergic receptor subtype has been cloned and emphasized as a
prototypic P2Z receptor involved in neurotransmission in the central nervou
s system and ATP-mediated lysis of macrophages in the immune system. Less i
s known about the neurobiology of P2X(7) receptors in the enteric nervous s
ystem (ENS). We studied the distribution of the receptor with indirect immu
nofluorescence and used selective agonists and antagonists to analyze pharm
acologic aspects of its electrophysiologic behavior as determined with intr
acellular "sharp" microelectrodes and patch-clamp recording methods in neur
ons identified morphologically by biocytin injection in the ENS. Applicatio
n of ATP or 2'- (or-3'-) O-(4-benzoylbenzoyl) adenosine 5'-triphosphate (Bz
BzATP) activated an inward current in myenteric neurons. Brilliant blue G,
a selective P2X(7) antagonist, suppressed the responses to both agonists. P
otency of the antagonist was greatest (smaller IC50) for the current evoked
by BzBzATP. The P2X(7) antagonists 1-[N,O-bis (1,5-isoquinolinesulfonyl)-N
-methyl-l-tyrosyl]-4-piperazine (KN-62) and oxidized ATP also suppressed th
e BzBzATP-activated current. Micropressure application of BzBzATP evoked ra
pidly activating depolarizing responses in intracellular studies with "shar
p" microelectrodes. Oxidized-ATP suppressed these responses in both myenter
ic and submucosal neurons. Rapidly activating depolarizing responses evoked
by application of nicotinic, serotonergic 5-HT3, or gamma -aminobutyric ac
id A (GABA(A)) receptor agonists were unaffected by brilliant blue G. Immun
oreactivity for the P2X(7) receptor was widely distributed surrounding gang
lion cell bodies and associated with nerve fibers in both myenteric and sub
mucous plexuses. P2X(7) immunoreactivity was colocalized with synapsin and
synaptophysin and surrounded ganglion cells that contained either calbindin
, calretinin, neuropeptide Y, substance P, or nitric oxide synthase. The mu
cosa, submucosal blood vessels, and the circular muscle coat also showed P2
X(7) receptor immunoreactivity. J. Comp. Neurol. 440:299-310, 2001. (C) 200
1 Wiley-Liss, Inc.